Landmesser, Ulf

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-Dinet, M., Bhatt, D. L., Bittner, V. A., Budaj, A. J., Diaz, R., Goodman, S. G., Hanotin, C., et al. (2019) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 315

Abnormal High-Density Lipoprotein Induces Endothelial Dysfunction via Activation of Toll-like Receptor-2

Speer, T., Rohrer, L., Blyszczuk, P., Shroff, R., Kuschnerus, K., Kränkel, N., Kania, G., Zewinger, S., Akhmedov, A., Shi, Y., et al. (2013) · Immunity

Nitric Oxide and Endothelin EffectsAtherosclerosis and Cardiovascular Diseases

Cited by 310

HDL cholesterol: reappraisal of its clinical relevance

März, W., Kleber, M. E., Scharnagl, H., Speer, T., Zewinger, S., Ritsch, A., Parhofer, K. G., von Eckardstein, A., Landmesser, U., & Laufs, U. (2017) · Clinical Research in Cardiology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 275

Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex

Huang, Y., Wu, Z., Riwanto, M., Gao, S., Levison, B. S., Gu, X., Fu, X., Wagner, M. A., Besler, C., Gerstenecker, G., et al. (2013) · Journal of Clinical Investigation

Paraoxonase enzyme and polymorphismsNeutrophil, Myeloperoxidase and Oxidative Mechanisms

Cited by 269

Tissue factor as a link between inflammation and coagulation

Witkowski, M., Landmesser, U., & Rauch, U. (2016) · Trends in Cardiovascular Medicine

Blood Coagulation and Thrombosis MechanismsBlood properties and coagulation

Cited by 240

Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis

Wright, R. S., Ray, K. K., Raal, F. J., Kallend, D. G., Jaros, M., Koenig, W., Leiter, L. A., Landmesser, U., Schwartz, G. G., Friedman, A., et al. (2021) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 229

Angiotensin II Induces Endothelial Xanthine Oxidase Activation: Role for Endothelial Dysfunction in Patients With Coronary Disease

Landmesser, U., Spiekermann, S., Preuss, C., Sorrentino, S., Fischer, D., Manes, C., Mueller, M., & Drexler, H. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology

Nitric Oxide and Endothelin EffectsGout, Hyperuricemia, Uric Acid

Cited by 210

Critical Role of the NAD(P)H Oxidase Subunit p47 phox for Left Ventricular Remodeling/Dysfunction and Survival After Myocardial Infarction

Doerries, C., Grote, K., Hilfiker-Kleiner, D., Luchtefeld, M., Schaefer, A., Holland, S. M., Sorrentino, S., Manes, C., Schieffer, B., Drexler, H., et al. (2007) · Circulation Research

Cardiac Fibrosis and RemodelingNitric Oxide and Endothelin Effects

Cited by 206

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

Landmesser, U., Chapman, M. J., Stock, J. K., Amarenco, P., Belch, J. J. F., Borén, J., Farnier, M., Ference, B. A., Gielen, S., Graham, I., et al. (2018) · European Heart Journal

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 200

Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial

Ray, K. K., Stoekenbroek, R. M., Kallend, D., Nishikido, T., Leiter, L. A., Landmesser, U., Wright, R. S., Wijngaard, P. L. J., & Kastelein, J. J. P. (2019) · JAMA Cardiology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 172

Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a)

Cho, L., Nicholls, S. J., Nordestgaard, B. G., Landmesser, U., Tsimikas, S., Blaha, M. J., Leitersdorf, E., Lincoff, A. M., Lesogor, A., Manning, B., et al. (2025) · American Heart Journal

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 169

Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration

Ference, B. A., Cannon, C. P., Landmesser, U., Lüscher, T. F., Catapano, A. L., & Ray, K. K. (2018) · European Heart Journal

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 161

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1

Ray, K. K., Stoekenbroek, R. M., Kallend, D., Leiter, L. A., Landmesser, U., Wright, R. S., Wijngaard, P., & Kastelein, J. J. P. (2018) · Circulation

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 154

Molecular Mechanisms in Heart Failure

Hilfiker-Kleiner, D., Landmesser, U., & Drexler, H. (2006) · Journal of the American College of Cardiology

Cardiac Fibrosis and RemodelingHeart Failure Treatment and Management

Cited by 151

The clinical significance of endothelial dysfunction

Landmesser, U., & Drexler, H. (2005) · Current Opinion in Cardiology

Nitric Oxide and Endothelin EffectsCardiovascular Health and Disease Prevention

Cited by 142

High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality

Silbernagel, G., Schottker, B., Appelbaum, S., Scharnagl, H., Kleber, M. E., Grammer, T. B., Ritsch, A., Mons, U., Holleczek, B., Goliasch, G., et al. (2013) · European Heart Journal

Lipoproteins and Cardiovascular HealthParaoxonase enzyme and polymorphisms

Cited by 123

Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial

Leiter, L. A., Teoh, H., Kallend, D., Wright, R. S., Landmesser, U., Wijngaard, P. L. J., Kastelein, J. J. P., & Ray, K. K. (2019) · Diabetes Care

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 117

Effect of inclisiran on lipids in primary prevention: the ORION-11 trial

Ray, K. K., Kallend, D., Leiter, L. A., Raal, F. J., Koenig, W., Jaros, M. J., Schwartz, G. G., Landmesser, U., Garcia Conde, L., Wright, R. S., et al. (2022) · European Heart Journal

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 116

Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial

Wright, R. S., Raal, F. J., Koenig, W., Landmesser, U., Leiter, L. A., Vikarunnessa, S., Lesogor, A., Maheux, P., Talloczy, Z., Zang, X., et al. (2024) · Cardiovascular Research

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 102

Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1

Landmesser, U., Haghikia, A., Leiter, L. A., Wright, R. S., Kallend, D., Wijngaard, P., Stoekenbroek, R., Kastelein, J. J., & Ray, K. K. (2021) · Cardiovascular Research

Lipoproteins and Cardiovascular HealthRNA Interference and Gene Delivery

Cited by 83

Micro–RNA-126 Reduces the Blood Thrombogenicity in Diabetes Mellitus via Targeting of Tissue Factor

Witkowski, M., Weithauser, A., Tabaraie, T., Steffens, D., Kränkel, N., Witkowski, M., Stratmann, B., Tschoepe, D., Landmesser, U., & Rauch-Kroehnert, U. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology

MicroRNA in disease regulationBlood Coagulation and Thrombosis Mechanisms

Cited by 79

Application of Magnetocardiography to Screen for Inflammatory Cardiomyopathy and Monitor Treatment Response

Brala, D., Thevathasan, T., Grahl, S., Barrow, S., Violano, M., Bergs, H., Golpour, A., Suwalski, P., Poller, W., Skurk, C., et al. (2023) · Journal of the American Heart Association

Viral Infections and Immunology ResearchCardiomyopathy and Myosin Studies

Cited by 54

Vascular miR-181b controls tissue factor-dependent thrombogenicity and inflammation in type 2 diabetes

Witkowski, M., Witkowski, M., Saffarzadeh, M., Friebel, J., Tabaraie, T., Ta Bao, L., Chakraborty, A., Dörner, A., Stratmann, B., Tschoepe, D., et al. (2020) · Cardiovascular Diabetology

MicroRNA in disease regulationBlood Coagulation and Thrombosis Mechanisms

Cited by 50

Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)

Sinning, D., & Landmesser, U. (2020) · Current Cardiology Reports

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 44